Neoadjuvant Chemotherapy for Breast Cancer: Recent Updates
Recent studies have revealed disappointing results for gemcitabine—but more support for taxane-first sequencing.
Advanced Breast Cancer
Palbociclib + Letrozole Improve Survival in Breast Cancer
Pfizer announced that the Phase 2 PALOMA-1 trial met its primary endpoint by achieving a statistically significant and clinically meaningful improvement in progression-free survival for the combination of palbociclib and letrozole vs. letrozole alone in postmenopausal women with ER+, HER2- advanced breast cancer.
Ramucirumab Does Not Improve Survival in Advanced Breast Cancer
Adding ramucirumab to docetaxel does not improve survival among patients with HER2-negative, advanced breast cancer.
Hormone Therapy in Breast Cancer
This fact sheet teaches patients how hormone therapy can help stop the growth of hormone-sensitive breast cancer tumors.
Number of Breast Cancer Gene Alterations Predicts Everolimus Benefit
The number of genetic alterations in tumors may predict which patients with breast cancer will benefit from adding everolimus to exemestane, found research presented at ASCO 2013.
Treating and Managing Inflammatory Breast Cancer
This fact sheet informs patients on how inflammatory breast cancer, symptoms, rashes are diagnosed, treated, and managed.
First in a New Approach to HER2-Positive Breast Cancer Approved
A new, cutting-edge treatment that links trastuzumab with DM-1 has been FDA-approved for advanced HER2-positive breast cancer.
Increase in Advanced Breast Cancer Seen in U.S. 25- to 39-Year-Olds
An increase in breast cancer with distant involvement is seen for young U.S. women of all races/ethnicities.
Emerging Therapeutic Approaches in Triple-Negative Breast Cancer
Approximately 15% to 20% of new breast cancer cases will be of the triple-negative phenotype, most of which are invasive ductal carcinomas.
SABCS: Investigational CDK Inhibitor Prolongs PFS among Women Taking Letrozole for Advanced ER+ Breast Cancer
Adding cyclin-dependent kinase (CDK) inhibitor PD 0332991 to letrozole therapy significantly prolongs progression-free survival among women with advanced estrogen receptor-positive breast cancer.
- Loading...
Loading...
Loading... 
Loading...